Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

J. Bousquet, P. van Cauwenberge, N. Aït Khaled, C. Bachert, C. E. Baena-Cagnani, J. Bouchard, C. Bunnag, G. W. Canonica, K.-H. Carlsen, Y.-Z. Chen, A. A. Cruz, A. Custovic, P. Demoly, R. Dubakiene, S. Durham, W. Fokkens, P. Howarth, J. Kemp, M. L. Kowalski, V. KvedarieneB. Lipworth, R. Lockey, V. Lund, S. Mavale-Manuel, E. O. Meltzer, J. Mullol, R. Naclerio, K. Nekam, K. Ohta, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. Popov, P. Potter, D. Price, G. Scadding, F. E. R. Simons, V. Spicak, E. Valovirta, D.-Y. Wang, B. Yawn, O. Yusuf

Research output: Contribution to journalReview articleAcademicpeer-review

130 Citations (Scopus)

Abstract

The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document
Original languageEnglish
Pages (from-to)1086-1096
JournalAllergy
Volume61
Issue number9
DOIs
Publication statusPublished - 2006

Cite this